{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:26:08Z","timestamp":1788272768837,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T00:00:00Z","timestamp":1703462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinical utility of Ki-67 immunohistochemistry (IHC) in breast cancer (BC) is mainly limited to decide for the use of chemotherapy and estimate prognosis in patients with either Ki-67 index\u2009&lt;\u20095% or\u2009&gt;\u200930%; however, lacunae still exists pertaining to its analytical validity. Neutrophilia is common in cancer with accompanying lymphocytopenia. Neutrophil to lymphocyte ratio (NLR) captures the intricate balance between pro-tumor neutrophilia and anti-tumor lymphocyte immunity. This study aimed to correlate cellular proliferation in breast cancer with NLR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An observational study was carried out including 73 cases of BC; pre-treatment NLR and Ki-67 grading were performed. NLR\u2009&lt;\u20093 was considered low, while\u2009\u2265\u20093 was high. The Ki-67 expression was graded as low\u2009\u2264\u20095%, intermediate 6\u201329%, or high\u2009\u2265\u200930%. Various clinico-pathological variables were studied, and the association of categorical variables was analyzed using Pearson\u2019s chi-square test, and a <jats:italic>p<\/jats:italic>-value of\u2009&lt;\u20090.05 was taken as significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ki-67 correlated significantly with modified Scarff-Bloom-Richardson (SBR) grade (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01), and tumor-node-metastasis (TNM) stage (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Correlation of NLR was not significant with SBR grade (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) and molecular subtype (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05); however, NLR was found to be significantly correlated with TNM stage (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and Ki-67 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>NLR is fast emerging as a personalized theranostic marker in breast cancer. Instead of determining a generalized cut-off value, individual baseline NLR and its dynamics with disease progression will help manage patients better, obviating some of the drawbacks associated with Ki-67.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43046-023-00200-4","type":"journal-article","created":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T01:01:56Z","timestamp":1703466116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Peripheral Neutrophil to Lymphocyte Ratio (NLR), a cogent clinical adjunct for Ki-67 in breast cancer"],"prefix":"10.1186","volume":"35","author":[{"given":"Radhika","family":"Arora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-0821","authenticated-orcid":false,"given":"Feroz","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atia","family":"Zaka-ur-Rab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,25]]},"reference":[{"key":"200_CR1","doi-asserted-by":"publisher","first-page":"e12252","DOI":"10.5812\/ijcm.12252","volume":"10","author":"Z Heidari","year":"2017","unstructured":"Heidari Z, Mahmoudzadeh- Sageb H, Jahantigh M, Charkhat Gorgich EA. Immunohistochemical expression of Ki 67 and HER2 in colorectal cancer compared to adenomatous and normal samples. Int J Cancer Manag. 2017;10:e12252. https:\/\/doi.org\/10.5812\/ijcm.12252.","journal-title":"Int J Cancer Manag"},{"key":"200_CR2","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41379-019-0260-6","volume":"32","author":"P Hammarsten","year":"2019","unstructured":"Hammarsten P, Josefsson A, Thysell E, Lundholm M, H\u00e4ggl\u00f6f C, Iglesias-Gato D, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod Pathol. 2019;32:1310\u20139. https:\/\/doi.org\/10.1038\/s41379-019-0260-6.","journal-title":"Mod Pathol"},{"key":"200_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12876-020-01484-9","volume":"20","author":"Z Wei","year":"2020","unstructured":"Wei Z, Huang L, Zhang X, Xu A. Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study. BMC Gastroenterol. 2020;20:343. https:\/\/doi.org\/10.1186\/s12876-020-01484-9.","journal-title":"BMC Gastroenterol"},{"key":"200_CR4","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.celrep.2018.06.110","volume":"24","author":"I Miller","year":"2018","unstructured":"Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a graded rather than a binary marker of proliferation versus quiescence. Cell Rep. 2018;24:1105\u201312.e5.","journal-title":"Cell Rep"},{"key":"200_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4048\/jbc.2014.17.1.40","volume":"17","author":"KI Kim","year":"2014","unstructured":"Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17:40\u20136.","journal-title":"J Breast Cancer"},{"key":"200_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-486","volume":"11","author":"PA Fasching","year":"2011","unstructured":"Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A, Bayer CM, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11:1\u20133.","journal-title":"BMC Cancer"},{"key":"200_CR7","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1200\/JCO.2016.71.9815","volume":"35","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Kueemmel S, et al. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the West German Study Group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2-and hormone receptor-positive phase II randomized trial-efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J Clin Oncol. 2017;35:3046\u201357.","journal-title":"J Clin Oncol"},{"key":"200_CR8","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1093\/jnci\/djr393","volume":"103","author":"M Dowsett","year":"2011","unstructured":"Dowsett M, Nielsen TO, A\u2019Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656\u201364.","journal-title":"J Natl Cancer Inst"},{"key":"200_CR9","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ. Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011;22:1736\u201347.","journal-title":"Ann Oncol"},{"key":"200_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000351692","volume":"8","author":"M Untch","year":"2013","unstructured":"Untch M, Gerber B, Harbeck N, Jackisch C, Marschner N, M\u00f6bus V, et al. 13th St. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a German team of experts (Zurich 2013). Breast Care. 2013;8:221\u20139. https:\/\/doi.org\/10.1159\/000351692.","journal-title":"Breast Care"},{"key":"200_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10549-016-3817-9","volume":"157","author":"S Bustreo","year":"2016","unstructured":"Bustreo S, Osella-Abate S, Cassoni P, Donadio M, Airoldi M, Pedani F, et al. Optimal Ki 67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157:363\u201371. https:\/\/doi.org\/10.1007\/s10549-016-3817-9.","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41598-019-57094-3","volume":"10","author":"X Zhu","year":"2020","unstructured":"Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, et al. The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci Rep. 2020;10:225. https:\/\/doi.org\/10.1038\/s41598-019-57094-3.","journal-title":"Sci Rep"},{"key":"200_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/11782234211016977","author":"MA Arafah","year":"2021","unstructured":"Arafah MA, Ouban A, Ameer OZ, Quek KJ. KI-67 LI expression in triple-negative breast cancer patients and its significance. Breast Cancer. 2021. https:\/\/doi.org\/10.1177\/11782234211016977.","journal-title":"Breast Cancer"},{"key":"200_CR14","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.3389\/fonc.2019.01068","volume":"9","author":"Q Wu","year":"2019","unstructured":"Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, et al. Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol. 2019;9:1068. https:\/\/doi.org\/10.3389\/fonc.2019.01068.","journal-title":"Front Oncol"},{"key":"200_CR15","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.3390\/cancers13174455","volume":"13","author":"MG Davey","year":"2021","unstructured":"Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel). 2021;13:4455. https:\/\/doi.org\/10.3390\/cancers13174455.","journal-title":"Cancers (Basel)"},{"key":"200_CR16","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/jnci\/djaa201","volume":"113","author":"TO Nielsen","year":"2021","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group. J Natl Cancer Inst. 2021;113:808\u201319. https:\/\/doi.org\/10.1093\/jnci\/djaa201.","journal-title":"J Natl Cancer Inst"},{"key":"200_CR17","doi-asserted-by":"publisher","first-page":"474","DOI":"10.4149\/BLL_2021_078","volume":"122","author":"R Zahorec","year":"2021","unstructured":"Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. 2021;122:474\u201388. https:\/\/doi.org\/10.4149\/BLL_2021_078.","journal-title":"Bratisl Lek Listy"},{"key":"200_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-016-0794-1","volume":"19","author":"JL Ethier","year":"2017","unstructured":"Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19:2.","journal-title":"Breast Cancer Res"},{"key":"200_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12885-015-1204-2","volume":"15","author":"M Pistelli","year":"2015","unstructured":"Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, Battelli N, et al. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015;15:195.","journal-title":"BMC Cancer"},{"key":"200_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep23115","volume":"6","author":"S Pu","year":"2016","unstructured":"Pu S, Qin B, He H, Zhan J, Wu Q, Zhang X, et al. Identification of early myeloid progenitors as immunosuppressive cells. Sci Rep. 2016;6:1\u20139.","journal-title":"Sci Rep"},{"key":"200_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.stem.2014.01.007","volume":"14","author":"JL Zhao","year":"2014","unstructured":"Zhao JL, Ma C, O\u2019Connell RM, Mehta A, DiLoreto R, Heath JR, et al. Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell. 2014;14:445\u201359.","journal-title":"Cell Stem Cell"},{"key":"200_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000346475","volume":"84","author":"K Kontzoglou","year":"2013","unstructured":"Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, et al. Correlation between Ki67 and breast cancer prognosis. Oncology. 2013;84:219\u201325.","journal-title":"Oncology"},{"key":"200_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.acthis.2016.05.002","volume":"118","author":"M Jurikova","year":"2016","unstructured":"Jurikova M, Danihel \u013d, Pol\u00e1k \u0160, Varga I. Ki67, PCNA, and MCM proteins: markers of proliferation in the diagnosis of breast cancer. Acta Histochem. 2016;118:544\u201352.","journal-title":"Acta Histochem"},{"key":"200_CR24","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","volume":"139","author":"EC Inwald","year":"2013","unstructured":"Inwald EC, Klinkhammer-Schalke M, Hofst\u00e4dter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539\u201352. https:\/\/doi.org\/10.1007\/s10549-013-2560-8.","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/jrms.JRMS_553_18","volume":"24","author":"H Kamranzadeh","year":"2019","unstructured":"Kamranzadeh H, Ardekani RM, Kasaeian A, Sadighi S, Maghsudi S, Jahanzad I, et al. Association between Ki-67 expression and clinicopathological features in prognosis of breast cancer: a retrospective cohort study. J Res Med Sci. 2019;24:30. https:\/\/doi.org\/10.4103\/jrms.JRMS_553_18.","journal-title":"J Res Med Sci"},{"key":"200_CR26","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.21873\/anticanres.11536","volume":"37","author":"F Thangarajah","year":"2017","unstructured":"Thangarajah F, Enninga I, Malter W, Hamacher S, Markiefka B, Richters L, et al. A retrospective analysis of Ki-67 index and its prognostic significance in over 800 primary breast cancer cases. Anticancer Res. 2017;37:1957\u201364. https:\/\/doi.org\/10.21873\/anticanres.11536.","journal-title":"Anticancer Res"},{"key":"200_CR27","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124.","journal-title":"J Natl Cancer Inst"},{"key":"200_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJK Guthrie","year":"2013","unstructured":"Guthrie GJK, Charles KA, Roxburgh CSD, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010.","journal-title":"Crit Rev Oncol Hematol"},{"key":"200_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10147-014-0672-8","volume":"20","author":"A Dirican","year":"2015","unstructured":"Dirican A, Kucukzeybek BB, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U, et al. Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer? Int J Clin Oncol. 2015;20:70\u201381. https:\/\/doi.org\/10.1007\/s10147-014-0672-8.","journal-title":"Int J Clin Oncol"},{"key":"200_CR30","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.22034\/APJCP.2017.18.8.2227","volume":"18","author":"\u00d6 Yersal","year":"2017","unstructured":"Yersal \u00d6, \u00c7etink\u00fcnar S, Aktimur R, Aziret M, \u00d6zda\u015f S, Erdem H, et al. Neutrophil\/lymphocyte and platelet\/lymphocyte ratios are not different among breast cancer subtypes. Asian Pac J Cancer Prev. 2017;18:2227\u201331. https:\/\/doi.org\/10.22034\/APJCP.2017.18.8.2227.","journal-title":"Asian Pac J Cancer Prev"},{"key":"200_CR31","first-page":"228","volume":"55","author":"F Elyasinia","year":"2017","unstructured":"Elyasinia F, Keramati MR, Ahmadi F, Rezaei S, Ashouri M, Parsaei R, et al. Neutrophil-lymphocyte ratio in different stages of breast cancer. Acta Med Iran. 2017;55:228\u201332. https:\/\/acta.tums.ac.ir\/index.php\/acta\/article\/view\/5704.","journal-title":"Acta Med Iran."},{"key":"200_CR32","doi-asserted-by":"publisher","first-page":"13078","DOI":"10.1038\/s41598-020-69965-1","volume":"10","author":"SJ Bae","year":"2020","unstructured":"Bae SJ, Cha YJ, Yoon C, Kim D, Lee J, Park S, et al. Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. Sci Rep. 2020;10:13078. https:\/\/doi.org\/10.1038\/s41598-020-69965-1.","journal-title":"Sci Rep"},{"key":"200_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.breast.2018.12.014","volume":"44","author":"V Graziano","year":"2019","unstructured":"Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, et al. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33\u20138. https:\/\/doi.org\/10.1016\/j.breast.2018.12.014.","journal-title":"Breast"},{"key":"200_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-022-06726-w","volume":"196","author":"Y Inoue","year":"2022","unstructured":"Inoue Y, Fujishima M, Ono M, Masuda J, Ozaki Y, Maeda T, et al. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer. Breast Cancer Res Treat. 2022;196:341\u20138. https:\/\/doi.org\/10.1007\/s10549-022-06726-w.","journal-title":"Breast Cancer Res Treat"},{"key":"200_CR35","doi-asserted-by":"publisher","first-page":"927491","DOI":"10.3389\/fsurg.2022.927491","volume":"9","author":"Z Ren","year":"2022","unstructured":"Ren Z, Yang J, Liang J, Xu Y, Lu G, Han Y, et al. Monitoring of postoperative neutrophil- to- lymphocyte ratio, D-dimer, and CA 153 in: diagnostic value for recurrent and metastatic breast cancer. Front Surg. 2022;9:927491. https:\/\/doi.org\/10.3389\/fsurg.2022.927491.","journal-title":"Front Surg"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-023-00200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-023-00200-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-023-00200-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,25]],"date-time":"2023-12-25T01:02:08Z","timestamp":1703466128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jenci.springeropen.com\/articles\/10.1186\/s43046-023-00200-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1186\/s43046-023-00200-4","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]},"assertion":[{"value":"28 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. The study was approved by the Institutional Ethics Committee, J.N Medical College,\u00a0AMU, Aligarh on 24.12.2019. , the registration no. of the certificate was\u00a0161\/FM\/IEC. Informed consent was obtained from the patients for obtaining the\u00a0biopsy tissue and peripheral blood.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}